Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | DTYMK | P23919 | 1/20 | 0.49 |
| ▸ | ESRRB | O95718 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496008 | 0.88 | KMT2A (0.61) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL17180311 | 0.86 | HTR2A (0.57) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL31093166 | 0.86 | KMT2A (0.57) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL5819280 | 0.86 | KMT2A (0.64) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL25306632 | 0.83 | GRIN2B (0.47) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL6768912 | 0.82 | KMT2A (0.59) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL1374093 | 0.81 | MEN1 (0.68) | ALDH1A1KDM4EPKMGPR119MEN1 | |
| SCHEMBL3556075 | 0.81 | CHRM2 (0.56) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL30702493 | 0.81 | CHRM2 (0.50) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 | |
| SCHEMBL29839089 | 0.81 | KMT2A (0.51) | CHRM3CHRM2CHRM4CHRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3927427-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-113748109-A | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11117881-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210188800-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021127472-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-101432278-A | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2009-05-13 | — | — | CN | disclosed |
| EP-2010525-A2 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | Brystol-Myers Squibb Company (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| WO-2007127635-A2 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127635-A2 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | CHRM3 4385/4885CHRM2 4243/4885CHRM4 4614/4885 |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | CHRM3 4385/4885CHRM2 4243/4885CHRM4 4614/4885 |
| US-20210188800-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | CHRM3 4385/4885CHRM2 4243/4885CHRM4 4614/4885 |
| US-11117881-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | CHRM3 4385/4885CHRM2 4243/4885CHRM4 4614/4885 |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | CHRM3 4732/4885CHRM2 4810/4885CHRM4 4794/4885 |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | CHRM3 4732/4885CHRM2 4810/4885CHRM4 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.